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3224Objective: Intraoperative tumor shedding may facilitate tumor dissemination. In earlier studies, shed tumor
cells were defined primarily by cytomorphological examination, and normal epithelial cells could not always
be distinguished from tumor cells. We sought to accurately identify tumor cells using single-cell sequencing
and determine whether these cells were mobilized into the circulation during pulmonary lobectomy.
Methods: Forty-two blood samples collected from the tumor-draining pulmonary vein at the end of lobectomy
procedures were analyzed. Arrays of nanowells were used to enumerate and retrieve single EpCAMþ cells. Tar-
geted sequencing of 10 to 15 cells and nested polymerase chain reaction of single cells detected somatic muta-
tions in shed epithelial cells consistent with patient-matched tumor but not normal tissue.
Results: Themean number of EpCAMþ cells in video-assisted thoracoscopy (VATS) lobectomy (nowedge) spec-
imens (n¼ 16) was 165 (median, 115; range, 0-509) but sampling cells from 3 patients indicated that only 0% to
38% of the EpCAMþ cells were tumor cells. The mean number of EpCAMþ cells in VATS lobectomy (wedge)
specimens (n¼ 12) was 1128 (median, 197; range, 47-9406) and all of the EpCAMþ cells were normal epithelial
cells in 2 patients sampled. The mean number of EpCAMþ cells in thoracotomy specimens (n¼ 14) was 238 (me-
dian, 22; range, 9-2920) and 0% to 50% of total EpCAMþ cells were tumor cells based on 4 patients sampled.
Conclusions: Surgery mobilizes tumor cells into the pulmonary vein, along with many normal epithelial cells.
EpCAM alone cannot differentiate between normal and tumor cells. On the other hand, single-cell genetic ap-
proaches with patient-matched normal and tumor tissues can accurately quantify the number of shed tumor cells.
(J Thorac Cardiovasc Surg 2014;148:3224-31)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surbut 30% of patients relapse and succumb to distant metasta-
ses or local recurrence.1 Intraoperative tumor shedding can
potentially contribute to tumor recurrence.2 Several studies
have reported incidences of tumor seeding during surgery,2,3
or local recurrences as a result of surgery.4 In particular, a
study by Yamanaka and colleagues3 sampled blood through
a catheter inserted into the mesenteric vein and found clus-
ters of tumor cells released into the circulation in patients
with colorectal cancers and portal invasion. In addition, a
no-touch isolation technique was developed to reduce intra-
operative tumor shedding.5,6 Therefore, it is of interest to
quantify how many tumor cells are dislodged during the
physical manipulation of the tumor during surgical resection.
In these earlier studies, shed tumor cells were identified
primarily by cytomorphological examination, immunohis-
tochemical staining, or indirect detection of epithelial cell
markers such as cytokeratin and EpCAMusing reverse tran-
scription (RT)-polymerase chain reaction (PCR).2,7-9 Using
cytokeratin staining, it was previously estimated that the
number of tumor cells shed during surgery ranged from
10 to 73 106.2 Another study reported a high number of tu-
mor cells found in the pulmonary vein (mean, 1195; me-
dian, 81) using EpCAM staining.8 It remains to be
determined, however, whether the tumor cell count is in-
flated by normal epithelial cells because none of the epithe-
lial markers used (cytokeratin or EpCAM) are tumorgery c December 2014
TABLE 1. Patient characteristics
No. of patients (%)
Sex
Male 17 (40)
Female 25 (60)
Age (y)
Mean 66
Range 45-86
Histology
Squamous cell carcinoma 8 (19)
Adenocarcinoma 33 (79)
Mixed 1 (2)
Pathologic stage
I 27 (64)
II 10 (24)
III 5 (12)
Smoking history
Smoker 37 (88)
Nonsmoker 5 (12)
Large vessel invasion
Positive 6 (14)
Negative 36 (86)
Small vessel/lymphatic invasion
Positive 9 (21)
Negative 33 (79)
Visceral pleura invasion
Positive 8 (19)
Negative 34 (81)
Abbreviations and Acronyms
MIT ¼ Massachusetts Institute of Technology
NSCLC ¼ non–small cell lung cancer
PBS ¼ phosphate-buffered saline
PCR ¼ polymerase chain reaction
PDMS ¼ poly(dimethylsiloxane)
VATS ¼ video-assisted thoracoscopy
WGA ¼ whole-genome amplification
Yao et al Evolving Technology/Basic Sciencespecific. The lack of single-cell isolation techniques when
performing genetic analysis such as RT-PCR also limits
the sensitivity of detection to about 10 cells.9,10 This
sensitivity may be suboptimal when the amount of tumor
cells shed is extremely small.
We made use of recent advances in single-cell isolation
techniques and genomic analysis11 to interrogate single
epithelial cells shed intraoperatively. Whole blood was ob-
tained from a ligated tumor-draining pulmonary vein and
individual epithelial cells were isolated using arrays of sub-
nanoliter wells (nanowells) developed previously.12 The
array comprises 84,762 cubic wells of 275 pL each. Because
shed cells are rare, loading biased the occupancy of the wells
to single epithelial cells. A robotic micromanipulator was
then used to retrieve individual cells for single-cell targeted
or whole-genome sequencing. Somatic mutations identified
in this highly enriched sample of shed epithelial cells were
compared against patient-matched tumor and adjacent
normal tissue, allowing us to pinpoint whether the shed cells
originated from the tumor.E
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SMATERIALS AND METHODS
Patients and Sample Collection
Patients were recruited according to a protocol approved by the Institu-
tional Review Board at the Lahey Hospital and Medical Center and a study
at Massachusetts Institute of Technology (MIT) approved by the Commit-
tee on the Use of Humans as Experimental Subjects. The patients identified
had biopsy-validated lung cancer, or had tumors suspicious for lung cancer
by computed tomography scan characteristics and/or positron emission to-
mography scan findings and had intraoperative diagnostic wedge resections
at the time of their lobectomy. Patients with lung cancer underwent lobec-
tomy either via thoracotomy or video-assisted thoracoscopy (VATS). Once
the lobe was removed, the remaining blood (1-8 mL) in the pulmonary vein
specimen was placed in a separate EDTA tube. If the tumor was at least 1.5
cm in size, then a segment of tumor measuring 5 mm3 5 mm3 5 mmwas
removed and placed in saline and on ice. A 2 cm3 2 cm3 1 cm segment of
the adjacent normal tissue was removed at least 8 cm outside the tumor
margin. The tissue specimens were transported to MIT within 2 hours.
Table 1 shows the patient characteristics (refer to Table E1 for individual
patient data).
Enrichment of Epithelial Cells From Blood Samples
The blood samples were enriched for epithelial cells using RosetteSep
CD45 depletion kits (Stemcell Technologies, Vancouver, Canada; refer
to Online Additional Methods). After depletion of CD45þ cells, the resid-
ual cells fromwhole blood were stained with EpCAM, a cocktail of lineageThe Journal of Thoracic and Carmarkers (Lin) for leukocytes including CD3, CD16, CD20, CD38, and
CD45 (all from Biolegend, San Diego, Calif) in a dilution of 1:20 and 1
mM Calcein Violet AM (Molecular Probes, Eugene, Ore) at room temper-
ature for 1 hour. The cells were then rinsed with phosphate-buffered saline
and stained with Annexin V FITC (BD Biosciences Pharmingen, San
Diego, Calif) in Annexin V binding buffer (BD Pharmingen) for 10minutes
at room temperature.
Cells were loaded onto the array of nanowells. The entire array was
imaged with an epifluorescence microscope (Carl Zeiss AG, Jena, Ger-
many) (refer to the Online Additional Methods for imaging specifications).
EpCAMþ cells were identified with Enumerator, custom image analysis
software developed in house. For each nanowell array, a list of cell infor-
mation was generated including the well ID, cell size, and fluorescent in-
tensities. The text file was converted into a FlowJo-readable text
format.13 Gating and cell statistics were analyzed in Flowjo (TreeStar
Inc, Aslnad, Ore) to identify the viable epithelial cells with their well
IDs (see Figure 1, A, for the workflow).
Single-Cell Retrieval
Enumerator generates a list of well positions containing epithelial
cells of interest. Borosilicate capillary tubing (internal diameter, 0.86
mm; outside diameter, 1.5 mm; length, 10 cm; Sutter Instrument Co, No-
vato, Calif) was purchased and shaped with a micropipette puller (Sutter
Instrument P-97). The tip was manually scored with a ceramic tile (Sutter
Instrument) to achieve an internal diameter of 50 to 60 mm, and mounted
on a robotic micromanipulator (CellCelector; AVISO GmbH, Jena, Ger-
many). The instrument was calibrated to the position of each well of the
array and instructed to retrieve the cells from the specified wells. The
robot aspirated 1 mL of medium directly above each well and deposited
the cells into a 96-well plate for downstream assays. The capillary tubediovascular Surgery c Volume 148, Number 6 3225
FIGURE 1. Isolation of intraoperatively shed tumor cells. A, Whole blood from the tumor-draining pulmonary vein was enriched by depletion of red and
white blood cells. The remaining cells were stained with fluorescent antibodies, loaded into nanowells and imaged for enumeration of epithelial cells. Viable
epithelial cells were defined as Calcein AMþ/Annexin V/EpCAMþ/Lin. Tumor and normal tissues were disaggregated into single-cell suspensions and
sorted by flow cytometry using the same markers. B, Image analysis software extracted the fluorescence intensities of all the cells on the array, which could
then be plotted similar to a flow cytometry plot. EpCAMþ cells were gated out and a list of their corresponding well IDs was generated. Single EpCAMþ
cells were retrieved with a robotic manipulator according to the well IDs. The robot only removed cells from a defined well (red box) but not from the neigh-
boring wells. EpCAMþ cells from normal and tumor tissues were harvested by flow cytometry. RBC, Red blood cells;WBC, white blood cells; FACS, flow-
activated cell sorting; Lin, lineage markers.
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Saspirates the contents from the well of interest but not the neighboring
wells (Figure 1, B).
Whole-Genome Amplification
Whole-genome amplification (WGA) was performed using the REPLI-
g single-cell kit (Qiagen, Limburg, The Netherlands). Ten to fifteen single
cells from blood samples were deposited into a single well containing 8 mL
of UltraPure water (Life Technologies, Inc, Rockville, Md), 0.3 mL of lysis
buffer (reconstituted in 55 mL of water) and 0.1 mL of 1 M dithiothreitol
buffer by the robot manipulator. The volume of aspiration was reduced
to 0.2 mL per cell. The cells were lysed at 65C for 10 minutes. Subse-
quently, 3 mL of Stop solution was added to quench cell lysis, followed
by 29 mL of reaction buffer and 2 mL of DNA polymerase. Isothermal
amplification was carried out at 30C for 8 hours.
Targeted Sequencing
Amplicon enrichment was performed using the Lung Cancer Panel
within the GeneRead DNAseq Targeted Exon Enrichment Panels for3226 The Journal of Thoracic and Cardiovascular SurNGS (Qiagen). Library preparation was done with the NEBNext DNA Li-
brary Prep Master Mix Set for Illumina (New England Biolabs, Beverly,
Mass) and barcoded with the NEBNext Multiplex Oligos for Illumina
(New England Biolabs). Sequencing of barcoded pools was performed
with paired-end 150 reads using the Illumina MiSeq and data were
analyzed using a combination of the Cloud-Based DNAseq Sequence
Variant Analysis (Qiagen).
Analysis of Copy Number Variation
WGA products were quantified using PicoGreen (Invitrogen Corpora-
tion, Carlsbad, Calif), adjusted to 2.5 ng/mL for library preparation using
the Nextera DNA Sample Prep Kit (Illumina Inc, San Diego, Calif), and
barcoded with the Nextera Index Kit (Illumina). Sequencing of barcoded
pools was performed with paired-end 150 reads using the Illumina MiSeq.
Mutation Analysis of Single Cells Using Nested PCR
Single cells from blood samples were deposited into 0.8% Triton X-100
in 15 mL of UltraPure water (Invitrogen) and 1 mL of Proteinase K (600gery c December 2014
Yao et al Evolving Technology/Basic SciencemAU/mL, Qiagen) by the robot manipulator as described in the cell
retrieval section. Cell lysis was achieved by 1 freeze-thaw cycle and Pro-
teinase K digestion for 1 hour at 55C. Two rounds of nested PCRs were
performed to amplify the exons of interest with a multiplex PCR kit (Qia-
gen). The first round of PCR amplification was performed for 15 cycles
(each cycle consisted of denaturation at 95C for 30 seconds, annealing
at 60C for 4 minutes, extension at 72C for 90 seconds). The second round
of PCR amplification was performed for 35 cycles (each cycle consisted of
denaturation at 95C for 30 seconds, annealing at 60C for 3 minutes,
extension at 72C for 90 seconds). Refer to Table E2 in the Online Data
Supplement for the primers used in p53 and kras sequencing.FIGURE 2. Count of EpCAMþ cells in the pulmonary vein. The number
of EpCAMþ cells in blood from the pulmonary vein was enumerated using
nanowells and plotted according to the type of surgery performed. Each bar
shows the median value. One zero value is excluded from the VATS (no
wedge) category. **P value<.001. VATS, Video-assisted thoracoscopy.RESULTS
Surgery Released EpCAMþ Cells into the Tumor-
Draining Pulmonary Vein
Forty-two patients with early-stage NSCLC recruited in
our study underwent either VATS lobectomy (with or
without diagnostic wedge) or thoracotomy and lobectomy.
In order to investigate whether tumor cells were shed intra-
operatively, whole blood (1-8mL) removed from the ligated
tumor-draining pulmonary vein was examined. Because tu-
mor cells are rare in the blood, we developed a platform to
enumerate and retrieve single cells (Figure 1). After the
epithelial cells were enriched by depletion of erythrocytes
and leukocytes, the remaining cells were loaded into an
array of 84,672 cubic wells and imaged for surface marker
expression. Viable epithelial cells in the blood were defined
as Calcein AMþ/Annexin V/EpCAMþ/Lin staining. The
nanowells partitioned the cells into units of single cells or
preformed clusters such that the robotic micromanipulator
retrieved only the viable epithelial cells from predetermined
wells of interest (Figure 1, B). Epithelial cells found in
normal and tumor tissues were isolated by flow cytometry
for comparison with the epithelial cells found in the blood.
Enumerating the number of viable cells using the nano-
wells revealed a significant number of EpCAMþ cells in
the pulmonary vein with counts as follows: VATS lobec-
tomy (no wedge) (mean, 165; median, 115; range 0-509),
VATS lobectomy (wedge) (mean, 1128; median, 197;
range, 47-9406), thoracotomy/lobectomy (mean, 238; me-
dian, 22; range, 9-2920) (Figure 2). The high number of
EpCAMþ cells in VATS lobectomy (wedge) was surprising
initially because the tumor tissue had already been removed
before the ligation of the pulmonary vein. This result
implied that many EpCAMþ cells were normal epithelial
cells. Therefore, we needed to differentiate between normal
and malignant epithelial cells using methods other than Ep-
CAM staining to accurately quantify the number of tumor
cells shed intraoperatively.E
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STargeted Sequencing Confirmed Consistent
Mutations Between Primary Tumor and Pulmonary
Vein Blood After Surgery
One accurate way to distinguish between normal and
tumor epithelial cells is to look for somatic mutationsThe Journal of Thoracic and Carunique to tumor cells. Ten to fifteen EpCAMþ cells
were retrieved from the pulmonary vein of each patient
and then pooled for targeted sequencing against a panel
of 20 frequently mutated genes in NSCLCs. Targeted
sequencing affords each gene a high coverage (typically
503 to 50003), enabling sensitive detection of low-
abundance somatic mutations from an admixture of
normal and tumor cells. The fraction of the reads mapped
to the alternate alleles indicates the abundance of tumor
cells (whereas the reference allele refers to the wild-
type/normal phenotype).
Targeted sequencing found that only a proportion of
EpCAMþ cells obtained from blood harbored the same so-
matic mutations as the patient-matched primary tumors
(Table 2). For VATS lobectomy (no wedge), 30% of the
reads from 2 patients (CW46 and CW48) contained point
mutations in TP53 and KRAS, respectively, whereas none
of the reads from patient CW54 contained the point muta-
tion present in the tumor. On the other hand, none of thediovascular Surgery c Volume 148, Number 6 3227
TABLE 2. Targeted sequencing
Patient ID Procedure Mutations
Tumor (%) Normal (%) Blood (%)
EpCAMþ cellsAlt Ref Alt Ref Alt Ref
CW46 VATS (no wedge) TP53, W91* 250 (90) 27 (10) 4 (0) 810 (100) 104 (30) 244 (70) 509
CW48 VATS (no wedge) KRAS, G12D 298 (27) 804 (73) 0 (0) 860 (100) 495 (26) 1382 (74) 131
CW54 VATS (no wedge) KRAS, G12C 183 (39) 285 (61) 60 (4) 1426 (96) 2 (2) 115 (98) 469
CW47 VATS (wedge) KRAS, G12C 296 (98) 7 (2) 0 (0) 524 (100) 0 (0) 34 (100) 53
CW61 VATS (wedge) KRAS, G13C 303 (97) 9 (3) 3 (0) 483 (100) 0 (0) 67 (100) 92
CW51 Thoracotomy TP53, R248Q 2337 (95) 129 (5) 8 (0) 5078 (100) 721 (14) 4370 (86) 31
CW56 Thoracotomy TP53, K120E 42 (20) 168 (80) 1 (0) 431 (100) 2 (0) 1435 (100) 30
CW59 Thoracotomy STK11, Y60* 2366 (100) 5 (0) 0 (0) 52 (100) 1 (10) 9 (90) 14
CW62 Thoracotomy EGFR, G719A 195 (17) 936 (83) 0 (0) 1648 (100) 182 (81) 44 (19) 2920
The whole-genome-amplification products of tumor, normal tissue, or shed epithelial cells found in the blood were used in targeted sequencing of 20 commonly mutated genes in
NSCLC. The table indicates the number of reads mapped to the reference alleles (indicating the presence of normal cells) or alternate alleles (indicating the presence of tumor
cells). Percentages of total reads are indicated in parentheses. Shown are 3 patients who underwent VATS (nowedge), 2 patients who underwent VATS (wedge), and 4 patients who
underwent thoracotomy. Alt, Alternate allele; Ref, reference allele; VATS, video-assisted thoracoscopy. *Stop codon.
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SVATS lobectomy (wedge) samples carried somatic muta-
tions in the blood specimens even though such mutations
were present in the primary tumors, implying that wedge
removed most if not all of the tumor tissue (Table 2). There-
fore, all of the EpCAMþ cells shed in the VATS lobectomy
(wedge) procedures that we examined were normal epithe-
lial cells.
The thoracotomy/lobectomy specimens gave a spectrum
of frequencies. Patient CW56 had no detectable mutations
in the blood specimen whereas patients CW51 and CW59
had approximately 10% of the reads containing the sameFIGURE 3. Copy number variation analysis. EpCAMþ cells from normal tiss
subjected to next-generation sequencing. The copy number variation analysis w
somes using a Hidden Markov Model. Chromosomal gains are colored in red;
derwent either: A, VATS (no wedge); B, VATS (wedge); or C, thoracotomy.
3228 The Journal of Thoracic and Cardiovascular SurTP53 mutation and STK11 mutation found in their respec-
tive primary tumors. Because patients CW51 and CW59
only had 31 and 14 EpCAMþ cells, 10% of the total
EpCAMþ cells yielded only 1 to 3 tumor cells, implying
that the number of tumor cells shed in these 2 patients
was almost negligible. On the other hand, the blood spec-
imen of patient CW62 had a high proportion of reads
(81%) harboring an activating EGFR mutation at codon
719. Because patient CW62 had 2920 EpCAMþ cells, a sig-
nificant number of tumor cells were shed intraoperatively in
this patient.ue, tumor tissue, and pulmonary veins were whole-genome amplified and
as performed with HMMCopy, a software program that segments chromo-
losses are colored in green; neutral copies are colored in blue. Patients un-
gery c December 2014
FIGURE 4. Nested PCR of single cells or single preformed clusters. The bulk tumor, normal tissue, and individual epithelial cells of the blood of 4 patients
were subjected to 2 rounds of PCR amplification reactions against specific somatic driver mutations in TP53, KRAS, and EGFR. The sequences of mutated
codons are indicated next to the patient ID with the normal tissue boxed in black and the tumor tissue boxed in red. The bright field and fluorescence images
Yao et al Evolving Technology/Basic Science
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SCopy Number Variation Analysis Confirmed the
Malignancy of Shed EpCAMþ Cells in the Blood
Although targeted sequencing identified single point mu-
tations, copy number variation allowed us to survey the
entire genomic landscape and determine the malignancy
based on chromosomal gains and losses. We performed a
low-pass copy number variation analysis between normal
tissue, tumor, and blood.
In general, the copy number variation analysis agreed
well with the targeted sequencing. In VATS lobectomy
(no wedge) specimens that contained a high tumor content,
such as CW46, the profile of the epithelial cells found in
the blood resembled that of the tumor tissue (Figure 3, A).
On the other hand, the profile of VATS lobectomy
(wedge) blood specimens such as CW47 was relatively
uniform (Figure 3, B), implying that no or few tumor
cells were released into the pulmonary vein. For the
thoracotomy/lobectomy patients with a low abundance of
tumor cells in the blood, such as CW51, the profile of the
blood was mostly uniform except in regions corresponding
to high chromosomal gains in the primary tumor (Figure 3,
C). On the other hand, patient CW62, with a high tumor
content in the blood, had chromosomal aberrations in the
blood specimen (Figure 3, C).Mutation Analysis of Single Cells Identified Tumor
Cells Released into the Pulmonary Vein During
Thoracotomy
Although targeted sequencing and copy number variation
analysis gave convincing evidence for the presence of shed
tumor cells, this analysis was conducted with pools of 10 to
15 cells (mainly because of cost limitations). We developed
a second method to detect somatic mutations applicable to
single cells and estimate the abundance of tumor cells.
Multiplex nested PCR followed by Sanger sequencing
was cost effective and sensitive down to single cells. We de-
signed multiplex primers against TP53 exons 4 to 8, KRAS
exon 2, and EGFR exons 18 to 21 because these regions
contain common mutations in NSCLC. For each patient,
we first confirmed the mutations present in the bulk tumors,
then screened for the same mutations in single cells of the
matched blood specimens.
Consistent with targeted sequencing, we detected indi-
vidual tumor cells and clusters of cells in VATS lobectomy
(no wedge) procedures. Two of 8 EpCAMþ cells from pa-
tient CW46 were tumor cells, and 3 of 8 EpCAMþ cells
from patient CW48 were tumor cells (Figure 4, A). Morpho-
logically, the tumor cells were larger and more irregularlyof single shed tumor cells are shown next to their sequences. Tumor cells are bo
cells. *A single tumor cell that has a mutation in KRAS F28S instead of the mo
underwent VATS (wedge) had no tumor cells shed. C, Patients CW50 and CW62
the 8 cells sampled were tumor cells. TL, Transmitted light; Lin, lineage marke
3230 The Journal of Thoracic and Cardiovascular Surshaped. No tumor cells were detected in the VATS lobec-
tomy (wedge) procedures in patients CW47 (Figure 4, B)
and CW61. In the thoracotomy/lobectomy samples, we
did not detect single tumor cells in patients CW50
(Figure 4,C), CW56, and CW59. However, 4 of 8 EpCAMþ
cells were tumor cells and contained the activating EGFR
G719A mutation in patient CW62 (Figure 4, C). Morpho-
logically, the tumor cells were indistinguishable from
normal cells, further supporting the inadequacy of using cy-
tomorphological means to quantify the number of tumor
cells.DISCUSSION
Although previous studies have reported an abundance of
intraoperatively shed cells,2,8 we used single-cell genetic
means to parse these cells into normal andmalignant epithe-
lial cells. We interrogated 421 EpCAMþ cells from 9 pa-
tients using 3 genetic approaches: single-cell nested PCR,
targeted sequencing, and copy number variation analysis.
We found that lobectomy mobilizes viable tumor cells
into the pulmonary vein. Other than tumor cells, a high
number of normal epithelial cells were also dislodged dur-
ing the surgery; these cells stained positive for EpCAM but
did not contain the same driver mutations as the ones found
in the primary tumors.
Many previous studies8,14,15 used EpCAM-based ap-
proaches to quantify the number of tumor cells shed during
surgery. Although nearly all EpCAMþ cells in the periph-
eral circulation (circulating tumor cells) are tumor cells,16
too many normal epithelial cells are dislodged during sur-
gery to render EpCAM an equally good marker for intrao-
peratively shed tumor cells. We found no correlation
between the number of EpCAMþ cells shed during surgery
and tumor size, lymph node metastases, blood vessel/
lymphatic invasion, or tumor grade (Figure E1), further sug-
gesting that EpCAM is limited as a marker of surgery-
induced tumor shedding. Genetic analysis is necessary to
differentiate between tumor and normal cells.
By using genetic approaches to pinpoint true tumor cells,
we have identified a group of patients who have significant
intraoperative tumor shedding. In our limited sample size,
we found that only 20% of the thoracotomy patients (1 of
5 patients) had significant tumor shedding. Patient CW62
had 1000 tumor cells mobilized into the pulmonary
vein. Other thoracotomy patients either had no detectable
tumor cells (CW50, CW56) or a very low number of tumor
cells based on the results of targeted sequencing (CW51,
CW59). A more extensive, longitudinal study is necessaryxed in red. A, Patient CW48 who underwent VATS (no wedge) had 3 tumor
re prevalent G12D mutation as in the primary tumor. B, Patient CW47 who
both underwent thoracotomy. CW50 had no tumor cells but in CW62, 4 of
rs.
gery c December 2014
Yao et al Evolving Technology/Basic Scienceto establish whether the number of tumor cells shed directly
affects patient outcome. The sample size of our current
study is too small to address this hypothesis. It also remains
to be determined whether the mobilized tumor cells are
capable of forming metastases.
In addition to sampling the pulmonary vein after the sur-
gery, we also sampled the peripheral blood and pulmonary
vein before surgical manipulation. However, the baseline
rate of tumor shedding is low (Figure E2). Although we
might not have captured all the baseline shedding using Ep-
CAM as a marker, the disparity between the number of cells
in the pulmonary vein after surgery and peripheral blood is
corroborated by a previous study.8 Because the number of
circulating tumor cells in patients with early-stage lung can-
cer is low, we believe that sampling the pulmonary vein af-
ter surgerymight provide an alternative noninvasivemethod
of identifying patients who may be at a higher risk of
recurrence.
Generally, more tumor cells were detected in the pulmo-
nary vein blood of the specimen from VATS lobectomy (no
wedge) procedures than thoracotomy/lobectomy proce-
dures. We believe that only the thoracotomy cases, not the
VATS cases, truly reflect the degree of tumor cell mobiliza-
tion as the manipulation of specimen after thoracotomy is
minimal. Once the lobe was extracted, we were careful
not to manipulate the tumor or lobe and only drained the
pulmonary vein by removing the staple line from the vein.
On the other hand, compression of the tumor during its
extraction by a VATS lobectomy may greatly inflate the
number of tumor cells shed.
The presence of mobilized tumor cells raises the question
as to whether the order and timing of pulmonary vein liga-
tion is important in minimizing this phenomenon. A recent
study compared the sequence of pulmonary vessel ligation
in patients undergoing thoracotomy and its impact on tumor
cell shedding using CD44v6 and CK19 as the tumor marker,
but the results showed no appreciable differences whether
the pulmonary vein was ligated before or after the ligation
of the pulmonary artery.17 It is possible that our genetic ap-
proaches may give a different count of tumor cells and
reveal a difference in the degree of tumor cell mobilization
during manipulation of the lobe during lobectomy.
In this study, we confirmed the presence of intraoperative
tumor cell shedding by identifying consistent mutations be-
tween EpCAMþ cells found in pulmonary vein blood and
the patient-matched tumor. It remains to be determined
whether the shed tumor cells are viable for any significant
length of time in the circulation or are potentiallyThe Journal of Thoracic and Cartumorigenic and whether these mobilized tumor cells influ-
ence local or systemic recurrence.
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Fabrication of Arrays of Nanowells
A silicone masterE1 was microfabricated (Stanford foundry) and
mounted in a metal mold. Poly(dimethylsiloxane) (PDMS) (Dow Corning)
(10:1 ratio of base to catalyst) was injected through a port into the silicone
mold, cured at 80C for 4 hours, and then removed to produce an array con-
taining 84,672 cubic wells (653 653 65 mm). Before use, the PDMS array
was oxygen plasma treated for 2 minutes and immediately submerged in
phosphate-buffered saline (PBS) to preserve the hydrophilicity rendered
by the plasma treatment. The array was then blocked in serum-containing
medium for 15 minutes before the cells were loaded.
Tumor Disaggregation and Flow Sorting
Tumor and adjacent normal tissues were cross-diced with a pair of scal-
pels, and resuspended in 2 mL of digest medium consisting of 1 mg/mL
collagenase A (Roche) and 1 mg/mL dispase (Stemcell Technologies).
The diced tissue was incubated on a shaking platform at 37C for 1 hour
(Figure 1, A). The digested tissue was then rinsed twice in PBS and stained
with the same antibodies as the blood samples and flow sorted into a 96-
well plate by FACSAria III (BDBiosciences) (Figure 1,B). The sorted cells
were frozen until further genomic analysis.
E-Reference
E1.Ogunniyi AO, Story CM, Papa E, Guillen E, Love JC. Screening individual hy-
bridomas by microengraving to discover monoclonal antibodies. Nat Protoc.
2009;4:767-82.
Enrichment of Epithelial Cells From Blood
Subsequently, 50 mL of antibody cocktail was added per milliliter of
whole blood and incubated for 20 minutes at room temperature. The blood
was then diluted with PBS in a 1:1 ratio and layered onto Ficoll-Paque Plus
(GE Healthcare, Little Chalfont, UK) in a SepMate tube (Stemcell Tech-
nologies) and centrifuged at 8003 g for 10 minutes. The upper layer con-
taining the serum and buffy coat was transferred to a new tube and washed
twice. Further red blood lysis was sometimes necessary to remove residual
red blood cells.
Microscopy
The following wavelengths were used to image the cells seeded on the
nanowells: Calcein Violet AM (excitation [Ex], 390 nm; emission [Em],
440/40 nm), AnnexinV-FITC (Ex, 488 nm; Em, 525/36 nm), EpCAM-
PerCP-eFluor710 (Ex, 488 nm; Em, 716/40 nm), Lin-PE/CY7 (Ex, 570
nm; Em, 809/81 nm).
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FIGURE E1. Correlation between the number of EpCAMþ cells shed and histologic features (A, tumor size; B, presence of lymph node metastases; C,
presence of blood vessel or lymphatic invasion; and D, tumor grade). The left panel includes all 42 patients (video-assisted thoracoscopy and thoracotomy)
and the right panel includes only the patients who underwent thoracotomy (14 patients). There is no significant correlation between the number of EpCAMþ
cells and the histologic features, suggesting EpCAM alone is not a good marker for quantifying the number of tumor cells shed intraoperatively.
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FIGURE E2. The number of EpCAMþ cells shed in peripheral blood
(n¼ 11 patients), pulmonary vein (PV) before the surgery (n¼ 21 patients)
and the pulmonary vein after the surgery (n ¼ 42 patients). The baseline
shedding of EpCAMþ cells is below detection in 5 mL of blood from
most patients.
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TABLE E1. Patient information
ID Procedure Sex Age Smoker Cancer stage Pathologic stage Pathology Grade
No. of
positive
nodes
Large
vessel
invasion
Small
vessel/lymphatic
invasion
Visceral
pleura
invasion
Tumor
size (cm)
Lobe
removed
No. of
EpCAMþ cells
CW1 VATS (wedge) M 68 1 IA (T1aN0M0) IA (T1aN0M0) Adeno 1 0 1.2 LUL 161
CW4 VATS (no wedge) M 73 1 IIA (T1aN1M0) IIA (T2aN1M0) Adeno 3 1 1 1 1 2.5 RML 277
CW5 VATS (no wedge) M 65 1 IB (T2aN0M0) IIA (T2aN1M0) Squam 2 1 1 3 LLL 272
CW6 VATS (no wedge) F 78 0 IA (T1aNoM0) IA (T1aN0M0) Adeno 2 0 1.3 LLL 20
CW7 VATS (wedge) F 72 1 IB (T2aN0M0) IB (T2aN0M0) Adeno 2 0 4 LUL 149
CW10 VATS (no wedge) M 53 1 IB (T2aN0M0) IB (T2aN0M0) Adeno 3 0 1 3.7 LLL 9
CW11 VATS (wedge) M 69 1 IB (T2aN0M0) IA (T1bN0M0) Adeno 2 0 3 LUL 632
CW12 Thoracotomy F 69 1 IIA (T1bN0M0) IIB (T3N0M0) Adeno 1 0 1 4 RLL 17
CW13 VATS (wedge) F 66 0 IA (T1aN0M0) IA (T1aN0M0) Adeno 1 0 1 LUL 423
CW14 VATS (wedge) F 53 1 IA (T1aN0M0) IB (T2aN0M0) Adeno 3 0 1 1 1 Wedge 9406
CW20 VATS (wedge) F 46 1 IA (T1aN0M0) IA (T1aN0M0) Adeno 1 0 1 RUL 1219
CW21 Thoracotomy F 61 0 IIB (T3N0M0) IIB (T3N0M0) Squam 3 0 1 5 RUL 10
CW22 Thoracotomy F 72 1 IIB (T3N0M0) IIB (T3N0M0) Squam 3 0 3.5 RUL 26
CW23 VATS (no wedge) M 75 1 IB (T2aN0M0) IIIA (T2aN2M0) Adeno 3 3 1 3.4 RLL 190
CW24 Thoracotomy F 76 1 IA (T1aN0M0) IB (T2aN0M0) Adeno 2 0 1 2.7 RUL 78
CW25 Thoracotomy F 66 1 IA (T1bN0M0) IA (T1bN0M0) Adeno 2 0 2.5 LUL 22
CW26 Thoracotomy M 69 1 IA (T1aN0M0) IA (T1aN0M0) Adeno 3 0 1 2 RUL 22
CW27 VATS (no wedge) M 66 1 IA (T1bN0M0) IA (T1aN0M0) Adeno 3 0 2 RUL 8
CW28 Thoracotomy M 70 1 IIA (T2bN0M0) IIA (T2bN0M0) Squam 3 0 1 6 Left pneum 12
CW29 Thoracotomy F 65 1 IIIA (T1aN2M0) IA (T1aN0M0) Adeno 2 0 0.9 RLL, RML 9
CW30 VATS (wedge) M 57 1 IA (T1aN0M0) IA (T1aN0M0) Adeno 3 0 1 2 RUL 104
CW41 VATS (wedge) M 56 1 IA (T1aN0M0) IA (T1aN0M0) Adeno 2 0 1.5 LUL tri 232
CW42 VATS (no wedge) M 58 1 IA (T1bN0M0) IA (T1bN0M0) Adeno 1 0 3.5 RUL 24
CW43 VATS (wedge) F 67 1 IA (T1bN0M0) IA (T1aN0M0) Adeno 3 0 2 RUL 1015
CW44 VATS (no wedge) F 79 1 IIA (T1aN1M0) IIIA (T1aN2M0) Adeno 2 5 1.5 RUL 99
CW45 VATS (no wedge) M 68 1 IA (T1aN0M0) IA (T1bN0M0) Squam 3 0 2.3 LLL 41
CW46 VATS (no wedge) M 62 1 IA (T1aN0M0) IIB (T2bN1M0) Adeno 3 6 3 RML, RLL 509
CW47 VATS (wedge) F 65 1 IA (T1aN0M0) IB (T2aN0M0) Adeno 3 0 1 1.5 RUL 53
CW48 VATS (no wedge) M 86 1 IIA (T1aN1M0) IIA (T2aN1M0) Adeno 3 2 1 1 4.5 RML, RLL 131
CW49 VATS (no wedge) F 76 1 IA (T1bN0M0) IA (T1bN0M0) Squam 3 0 2.8 RLL 21
CW50 Thoracotomy F 59 1 IIB (T3N0M0) IIIA (T3N1M0) Adeno 3 2 7 RLL 17
CW51 Thoracotomy F 64 1 IIA (T1bN1M0) IIIA (T1bN2M0) 15% squam, 70%
large neuro, 10% small
4 8 1 1 3 RML, RLL 31
CW53 VATS (no wedge) M 79 1 IA (T1bN0M0) IA (T1bN0M0) Squam 2 0 1 3 RUL 140
CW54 VATS (no wedge) F 55 1 IA (T1aN0M0) IA (T1aN0M0) Adeno 2 0 1.1 RLL 469
CW55 VATS (no wedge) F 86 1 IIB (T3N0M0) IB (T2aN0M0) Adeno 2 9 4 LUL 433
CW56 Thoracotomy M 62 1 IB (T2aN0M0) IB (T2aN0M0) Squam 2 0 4 RLL 30
CW57 VATS (no wedge) F 59 1 IA (T1aN0M0) IIB (T3N0M0) Adeno 2 0 1.8 and 7 mm RUL 0
CW58 Thoracotomy F 45 0 IIIA (T1aN2M0) IIIA (T1aN2M0) Adeno 4 10 1 1 1 1.5 RML 120
CW59 Thoracotomy F 69 1 IIB (T3N0M0) IIB (T3N0M0) Adeno 1 0 9 RUL, RML 14
CW60 VATS (wedge) F 63 0 IA (T1bN0M0) IA (T1aN0M0) Adeno 1 0 1.5 RLL 47
CW61 VATS (wedge) F 57 1 IA (T1aN0M0) IA (T1aN0M0) Adeno 2 0 1.2 RUL 92
CW62 Thoracotomy F 63 1 IA (T1bN0M0) IA (T1bN0M0) Adeno 3 0 3 RLL 2920
VATS, Video-assisted thoracoscopy;M, male; F, female; Adeno, adenocarcinoma; Squam, squamous cell carcinoma; LUL, left upper lobe; RML, right middle lobe; LLL, left lower lobe; RLL, right lower lobe; RUL, right upper lobe;
pneu, pneumonectomy; tri, trisegmentectomy; neuro, neuro-endocrine; small, small cell.
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TABLE E2. List of primers used for nested PCR of single cells to detect mutations in TP53, KRAS, and EGFR
Gene Exon PCR Direction Sequence (50 to 30)
TP53 4 Outer Forward CTGAGGACCTGGTCCTCTGACT
TP53 4 Outer Reverse GGCCAGGCATTGAAGTCTCAT
TP53 4 Inner Forward ACCTGGTCCTCTGACTGCTCTT
TP53 4 Inner Reverse AAGCCAGCCCCTCAGGGCAA
TP53 4 Sequencing Forward CCTGGTCCTCTGACTGCTCTTTTCACCCA
TP53 5 Outer Forward GCTCGCTAGTGGGTTGCAGGAGGTGC
TP53 5 Outer Reverse TGTCGTCTCTCCAGCCCC
TP53 5 Inner Forward TGCTGCCGTGTTCCAGTTGCT
TP53 5 Inner Reverse TGTCGTCTCTCCAGCCCC
TP53 5 Sequencing Forward CAACTCTGTCTCCTTCCT
TP53 6 Outer Forward GGCTGGTTGCCCAGGGTCC
TP53 6 Outer Reverse GGTCAAATAAGCAGCAGGAGAAAGCCCCC
TP53 6 Inner Forward GGCTGGTTGCCCAGGGTCC
TP53 6 Inner Reverse CTTAACCCCTCCTCCCAGAG
TP53 6 Sequencing Forward GGTCCCCAGGCCTCTGATTCC
TP53 7 Outer Forward GCCACAGGTCTCCCCAAGGCG
TP53 7 Outer Reverse AGCGGCAAGCAGAGGCTGGG
TP53 7 Inner Forward CGCACTGGCCTCATCTTGGGC
TP53 7 Inner Reverse AGTGTGCAGGGTGGCAAGTG
TP53 7 Sequencing Forward CCTCATCTTGGGCCTGTGTT
TP53 8 Outer Forward GGCTCCAGAAAGGACAAGGGTGG
TP53 8 Outer Reverse ATAACTGCACCCTTGGTCTC
TP53 8 Inner Forward TGGGAGTAGATGGAGCCTGGT
TP53 8 Inner Reverse CCCTTGGTCTCCTCCACCGCT
TP53 8 Sequencing Forward CCTTACTGCCTCTTGCTTCT
KRAS 2 Outer Forward CGTCTGCAGTCAACTGGAAT
KRAS 2 Outer Reverse TCATGAAAATGGTCAGAGAAACC
KRAS 2 Inner Forward GGTGGAGTATTTGATAGTGTATTAACC
KRAS 2 Inner Reverse GGTCCTGCACCAGTAATATGC
KRAS 2 Sequencing Forward TTAACCTTATGTGTGACATGTTCTAA
EGFR 18 Outer Forward GCGTACATTTGTCCTTCCAAATGAGCTGG
EGFR 18 Outer Reverse AGATGATGGAAATATACAGCTTGCAAGGAC
EGFR 18 Inner Forward CCGTGTCCTGGCACCCAAGC
EGFR 18 Inner Reverse TCTGGGCTCCCCACCAGACC
EGFR 18 Sequencing Forward TGGTGAGGGCTGAGGTGACCC
EGFR 19 Outer Forward GCTCCACAGCCCCAGTGTCC
EGFR 19 Outer Reverse CAGCATGGGAGAGGCCAGTGC
EGFR 19 Inner Forward CCTTCGGGGTGCATCGCTGG
EGFR 19 Inner Reverse GCCATGGACCCCCACACAGC
EGFR 19 Sequencing Forward GGGCAGCATGTGGCACCATCTC
EGFR 20 Outer Forward ACAGCCCTGCGTAAACGTCCC
EGFR 20 Outer Reverse GCTGCATGCACGCACACAC
EGFR 20 Inner Forward TGGCCACCATGCGAAGCCAC
EGFR 20 Inner Reverse GGAGCGCAGACCGCATGTGAG
EGFR 20 Sequencing Forward GCCACACTGACGTGCCTCTCC
EGFR 21 Outer Forward AGTCACTAACGTTCGCCAGCC
EGFR 21 Outer Reverse CAGCTGCTGCGAGCTCACCC
EGFR 21 Inner Forward TCCTCGACGTGGAGAGGCTCAG
EGFR 21 Inner Reverse GCAGCCTGGTCCCTGGTGTC
EGFR 21 Sequencing Forward ACCCTGAATTCGGATGCAGAGCTTC
PCR, Polymerase chain reaction.
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